Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

New Sub-Analysis of RE-LY Trial Examines Pradaxa in Patients with Atrial Fibrillation Undergoing Cardioversion

January 5, 2011 By Bio-Medicine.Org

RIDGEFIELD, Conn., Jan. 5, 2011 /PRNewswire/ — Results of a
post-hoc analysis of the RE-LY® trial among patients with
non-valvular atrial fibrillation (NVAF) undergoing cardioversion, a
treatment to convert an abnormal heartbeat back to normal sinus
rhythm, were published online on Jan. 3 in Circulation.(1)
 Stroke and systemic embolism and major bleeding episodes
within 30 days of the cardioversion were the major outcome
measures.  The analysis reported that rates of stroke and
systemic embolism and major bleeding were low and comparable to
warfarin in cardioverted patients receiving Pradaxa®
(dabigatran etexilate mesylate) 150mg capsules,(1) an oral
anticoagulant recently approved by the U.S. Food and Drug
Administration (FDA) to reduce the risk of stroke and systemic
embolism in patients with NVAF.(2)

In RE-LY, a total of 1,983 cardioversions were performed in
1,270 patients, with similar numbers in each treatment group (647
in the dabigatran 110mg* group, 672 in the PRADAXA 150mg group and
664 in the warfarin group).(1)  Rates of stroke and systemic
embolism within 30 days of cardioversion were low and did not
differ significantly between treatment arms (0.77%, 0.3% and 0.6%,
respectively; dabigatran 110mg vs. warfarin, p=0.71; PRADAXA 150mg
vs. warfarin, p=0.45),(1) though the RE-LY trial and this subgroup
analysis were not powered to demonstrate statistical significance.
 Similarly, major bleeding within 30 days of cardioversion was
infrequent and comparable between treatment groups (1.7%, 0.6% and
0.6%, respectively).(1)

“Cardioversion is one treatment option for patients with atrial
fibrillation and requires anticoagulation both prior to and
following treatment in order to reduce the risk of stroke,” said
Rangadham Nagarakanti, MD, Louisiana State University School of
Medicine.  “It’s helpful to know that patients on PRADAXA who
underwent cardioversion had low rates of stroke and systemic
embolism

‘/>”/>

SOURCE

Related Articles Read More >

TE Connectivity opens global medical device prototyping center in Ireland
Prix Galien USA 2022 nominees
The 24 best medical device innovations of 2022
A portrait of Ellen Roche, MIT School of Engineering associate professor
New implant design prevents scar tissue without drugs, MIT says
UMN artificial blood vessel clinical trial
Minnesota researchers awarded $3.7M grant for artificial, bioengineered blood vessel clinical trial

DeviceTalks Weekly.

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech